Download PDF
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2021; 13(04): 231-235
DOI: 10.4103/ijmbs.ijmbs_3_21
Case Report

Severe hyperglycemia in an insulin-deficient patient with type 2 diabetes responding well to oral antidiabetic therapy

Akrem M. Elmalti
1   Rashid Centre for Diabetes and Research, Ajman
,
Mamoun Mukhtar
1   Rashid Centre for Diabetes and Research, Ajman
,
Sijomol Skaria
1   Rashid Centre for Diabetes and Research, Ajman
,
Wafa Harbagi
1   Rashid Centre for Diabetes and Research, Ajman
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease characterized by a steady decline in beta-cell function and insulin resistance. As a result, most patients with T2DM may require treatment with insulin after 15–20 years of diagnosis. Various pathophysiological defects were identified leading to hyperglycemia, including reduced insulin secretion due to beta-cell failure. They reduced beta-cell mass and a defect in insulin secretion, which leads to a relative insulin deficiency in these patients requiring insulin treatment. Most international guidelines recommend starting insulin treatment in patients with poor glucose control, mainly if the glycated hemoglobin (HbA1c) is above 9% with the presence of symptoms, especially in relatively newly diagnosed patients with T2DM. We present a 45-year-old patient with T2DM of 5 years duration who attended our center with severe hyperglycemia with evidence of insulin deficiency both clinically and biochemically, who responded well to oral antidiabetic agents achieving adequate glycemic control.

Key-words:

Glucose toxicity - glucotoxicity - insulin deficiency - insulin treatment - type 2 diabetes

Financial support and sponsorship

Nil.




Publication History

Received: 05 January 2021

Accepted: 05 July 2021

Article published online:
14 July 2022

© 2021. The Libyan Authority of Scientific Research and Technologyand the Libyan Biotechnology Research Center. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License,permitting copying and reproductionso long as the original work is given appropriate credit. Contents may not be used for commercial purposes, oradapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-79.
  • 2 Garber AJ, Handelsman Y, Grunberger G, Einhorn D, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2020 executive summary. Endocr Pract 2020;26:107-39.
  • 3 National Institute for Health and Care Excellence. Management for Type 2 Diabetes in Adults: NICE Guideline Published; 2 December, 2015. Available from: https://www.nice.org.uk/guidance/ng28. [Last accessed on 2021 Jun 22].
  • 4 Robertson R, Harmon J, Tran P, Tanaka Y, Takahashi H. Glucose toxicity in beta-cells: Type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003;52:581-7.
  • 5 Kaiser Ν, Leibowitz G, Nesher R. Glucotoxicity and β-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003;16:5-22.
  • 6 Robertson R, Olson L, Zhang H. Differentiating glucose toxicity from glucose desensitization: A new message from the insulin gene. Diabetes 1994;43:1085-9.
  • 7 King WM 4th, McDermott MT, Trujillo JM. Initial management of severe hyperglycemia in people with type 2 diabetes: An observational study. Diabetes Ther 2013;4:375-84.
  • 8 Davidson MB. Successful treatment of markedly symptomatic patients with type II diabetes mellitus using high doses of sulfonylurea agents. West J Med 1992;157:199-200.
  • 9 Babu A, Mehta A, Guerrero P, Chen Z, Meyer PM, Koh CK, et al. Safe and simple emergency department discharge therapy for patients with type 2 diabetes mellitus and severe hyperglycemia. Endocr Pract 2009;15:696-704.
  • 10 Amblee A, Lious D, Fogelfeld L. Combination of saxagliptin and metformin is effective as initial therapy in new-onset type 2 diabetes mellitus with severe hyperglycemia. J Clin Endocrinol Metab 2016;101:2528-35.